How GLP-1 Medications Actually Work for Weight Loss in 2026

Last updated: November 2026 · Written by the ClearMetabolic team

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) have become the most effective weight loss medications available. In the main obesity trials, average weight loss at the target doses ranged from about 15% to 21% of body weight. I have been on tirzepatide for over a year, tracking everything with DEXA scans, and the results have been real.

What GLP-1 Medications Do in Your Body

GLP-1 stands for glucagon-like peptide-1. Your gut naturally produces it after meals. These medications mimic that hormone, but at much higher levels and for much longer.

Here is what happens when you inject a GLP-1 medication:

Appetite drops significantly. The drug signals your brain’s satiety center directly. Food noise (that constant background thinking about food) goes quiet. This was the first thing I noticed on Mounjaro.
Stomach empties slower. Food sits in your stomach longer, so you feel full after smaller portions. This also explains the most common side effect: nausea, especially during dose increases.
Blood sugar stabilizes. GLP-1s were originally diabetes drugs. They help your pancreas release insulin more effectively and reduce blood sugar spikes after meals.
Cravings decrease. Research suggests these drugs affect reward pathways in the brain, reducing the pull toward high-calorie foods.

The net effect is simple: you eat less without white-knuckling it. That caloric deficit drives the weight loss.

What the Clinical Data Shows

The numbers from major trials are striking:

Semaglutide 2.4mg (Wegovy): Average 14.9% body weight loss over 68 weeks in the STEP 1 trial, compared with 2.4% on placebo. About half (50.5%) of people on semaglutide lost 15% or more.
Tirzepatide (Zepbound): Average weight loss of 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) over 72 weeks in the SURMOUNT-1 trial, compared with 3.1% on placebo. About half of people on the 10 mg and 15 mg doses lost 20% or more.

These are averages. Individual results vary a lot in both directions. Genetics, starting weight, diet, and exercise all play a role.

Compare GLP-1 providers and pricing

See Provider Comparison →

What I Have Learned on Tirzepatide

I started tracking my body composition with DEXA scans before and during treatment. A few things stood out:

Muscle loss is real if you do not train. GLP-1 medications cause weight loss from both fat and lean mass. In the DEXA subgroups of the trials, lean mass (muscle plus water, organs and other non-fat tissue) made up roughly 39% of the weight lost in STEP 1 and roughly 25% in SURMOUNT-1. I prioritized lifting 3-4 days per week and kept protein above 1g per pound of lean mass. My DEXA scans showed the majority of my loss came from fat.

Side effects improve over time. The nausea was rough during the first two dose increases. By month three, it was barely noticeable. Eating smaller meals and staying hydrated helped.

The cost question matters. As of Nov 4, 2026, Novo Nordisk lists self-pay Wegovy pens at $349 per month (with a $199 offer for the first two fills of the lowest doses) on NovoCare. Lilly lists self-pay Zepbound at $299 (2.5 mg), $399 (5 mg) and $449 (7.5 mg to 15 mg, with a refill-timing condition) on LillyDirect. The FDA declared the semaglutide and tirzepatide shortages over, which limits legal compounding of copies. See our compounded vs brand-name guide and the provider comparison for current options.

What to Expect Month by Month

The timeline surprised me. Weight loss is not linear, and the first month is more about adjustment than results.

Month 1 (starter dose): Most people barely lose weight on the lowest dose. That is by design. The starter dose exists to let your gut adjust and reduce nausea, not to drive loss. If the scale does not move in weeks 1-4, that is normal. I lost about 3 pounds.
Months 2-3 (dose increases): This is where appetite suppression kicks in hard. As the dose steps up (no faster than every four weeks per the Wegovy and Zepbound labels), the food noise goes quiet and portions shrink on their own. Most of my early fat loss happened here.
Months 4-6 (maintenance dose): Loss usually continues at a steadier pace. Side effects often settle. This is the stretch where resistance training matters most, because a bigger deficit means more risk to lean mass.
Months 9-12 and beyond: Loss slows as you approach a new set point. In STEP 1 and SURMOUNT-1, average weight loss kept going for more than a year and leveled off toward the end of the 68- and 72-week trials, so the tail is long. This is also where the maintenance question becomes real.

Managing the Side Effects

Nausea is the one almost everyone hits. A few things that actually helped me:

Eat smaller meals and stop before you feel full, because delayed stomach emptying means “full” arrives late.
Cut back on greasy and high-fat meals during dose increases. They sit heavy.
Stay hydrated. Constipation is common, and water plus fiber handles most of it.
If a dose increase feels rough, ask your prescriber about holding at the current dose longer. The Wegovy label itself says to consider delaying escalation for 4 weeks if a dose is not tolerated. There is no prize for climbing fast.
Call your prescriber about severe or persistent belly pain (possible pancreatitis or gallbladder problems) or vomiting that stops you keeping fluids down, which can lead to kidney injury. Both labels carry a boxed warning about thyroid C-cell tumors, and these drugs should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy.

Who Should Consider GLP-1 Medications

For weight loss, the Wegovy and Zepbound labels cover adults with obesity, or with overweight plus at least one weight-related condition like type 2 diabetes or high blood pressure. In practice that usually means a BMI of 30+, or 27+ with a weight-related condition. Wegovy is also approved for teens 12 and older with obesity. They are not cosmetic weight loss drugs for people looking to drop 5 pounds.

If you are considering GLP-1 treatment, start with our cheapest GLP-1 options guide to understand pricing, or browse provider reviews from people who have used these services.

What we checked

This AI-assisted public-source desk check reviewed the STEP 1 and SURMOUNT-1 trial reports, the FDA prescribing information for Wegovy and Zepbound, the FDA compounding policy update, and the NovoCare and LillyDirect self-pay price pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.